Homepage > Company > Media > Pharma News > 2020 > China's Sinovac enters supply deal with Indonesia for COVID-19 vaccine doses

China's Sinovac enters supply deal with Indonesia for COVID-19 vaccine doses

(Reuters) - Sinovac Biotech Ltd said on Tuesday it would help Indonesia’s state-owned drugmaker Bio Farma produce in the country at least 40 million doses of its potential coronavirus vaccine before March 2021.

The U.S.-listed Chinese drugmaker has signed two agreements with Bio Farma for supply, local production and technology licensing of its vaccine candidate CoronaVac and the Indonesian company is conducting the late-stage study of the candidate.

Sinovac will continue to supply the bulk vaccine until the end of 2021 after March, it said in a statement.

There are no approved vaccine for COVID-19, with drugmakers and research organizations racing to develop a safe and effective vaccine that is seen as crucial to combat the pandemic.

AUGUST 25, 2020

https://www.reuters.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)